Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Conditions
Brief summary
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
Detailed description
This is a Phase 2, open-label clinical trial study that aims to evaluate the efficacy (eg. Complete response, Overall Survival, Progression Free Survival) and adverse effects of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
Interventions
DRUGChidamide combined with Linperlisib
Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
Sponsors
Fujian Provincial Hospital
Fujian Cancer Hospital
Zhangzhou Affiliated Hospital of Fujian Medical University
Jieyang People's Hospital
Dongguan People's Hospital
Huizhou Municipal Central Hospital
The First Affiliated Hospital with Nanjing Medical University
Sun Yat-sen University
Shanxi Province Cancer Hospital
The First Affiliated Hospital of Xiamen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The patients diagnosed with follicular lymphoma with grade 1-3a, have received at least second-line systemic treatment, and at least one of the first-line treatments includes anti-CD20 monoclonal antibody (anti-CD20 monoclonal antibody monotherapy or combined chemotherapy). If the latest histopathological diagnosis is more than 6 months, a lymph node or tissue puncture or biopsy (resection or coarse needle puncture) must be performed. 2. Age ≥18 years old, regardless of gender. 3. The estimated survival time is more than 3 months. 4. ECOG ≤ 2. 5. Be able to follow the requirements of the research plan. 6. The patients have at least one measurable lesion (any length of lymph node lesion \> 1.5cm or any length of extranodal lesion \> 1 cm) examined by computed tomography (CT)/ magnetic resonance imaging (MRI). 7. Be able to understand and voluntarily provide informed consent.
Exclusion criteria
1. CNS involvement (current or previous). 2. Clinical evidence of transformation to a more aggressive subtype of lymphoma 3. Impaired bone marrow function: neutrophils \< 1.5× 10\*9/L, HB \< 80 g/L, PLT \< 75×10\*9 /L, Impaired liver function, defined as serum total bilirubin \> 1.5 x ULN or serum ALT and AST \> 2.5x ULN, Patients with liver infiltration by lymphoma, AST and ALT \> 5x ULN, Renal glomerular filtration rate (eGFR) \< 30 ml/min. 4. PT INR\>1.5ULN or APTT\> 1.5 ULN, Serum amylase or lipase \> 1ULN. 5. Patients with active infection of the human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV), if patients with HBV infection with HBsAg or hepatitis B core antibody (HBcAb) positive\] but HBV DNA negative can be included, However, these patients need continuous antiviral treatment and HBV DNA PCR detection every cycle after enrollment. 6. Patients with CMV infection (IgM positive or CMV DNA was positive by PCR.) 7. Meet any of the following criteria related to visceral function: all kinds of clinically significant abnormal rhythm or conduction need clinical pre-diagnosis Hereditary QT interval syndrome or QTcF\>480 msec or taking drugs that may cause Qt interval delay or torsade de pointes. A variety of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months of the group, with New York's cardiology (NYHA) classification of grade 3 or above. Left ventricular ejection fraction (LVEF )\<40%, or uncontrolled blood pressure controlled by drugs (Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mgHg). 8. Have a history of stroke or intracranial hemorrhage within 6 months before drug administration for the first time. 9. Major surgery was performed within 4 weeks before enrollment. 10. Any PI3K inhibitor has been used before and the disease has progressed during the treatment period (within 6 months after the last use). 11. Received systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment. 12. The last time you participated in clinical trials of other drugs before enrollment was less than 2 weeks or the last time you used small molecular drugs (such as antibody drugs) was less than 4 weeks. 13. The patients received the transplantation of somatic hematopoietic stem cells within 3 months before enrollment. 14. Patients received allogeneic hematopoietic stem cell transplantation or had any active graft-versus-host disease within 6 months before drug administration. 15. Take a strong inducer or inhibitor of cytochrome P4503A4 (CYP3A4) within 2 weeks before the first drug administration (3 weeks for Hypericum perforatum) 16. Before the first drug administration, the toxic reaction of previous anti-tumor therapy has not recovered to ≤1 level (except alopecia). 17. Patients with uncontrolled systemic infection requiring intravenous antibiotic treatment. 18. Currently suffering from other primary tumors that need active treatment according to the guidelines. 19. Inability to take drugs orally, previous surgical history, or serious gastrointestinal diseases such as dysphagia and active gastric ulcer may affect the absorption of drugs. 20. Pregnant (serum pregnancy test results are positive) or lactating women 21. Any other diseases, abnormal metabolism, abnormal physical examination, or abnormal laboratory examination with significant clinical significance, according to the researcher's judgment, it is reasonable to suspect that the patient has a certain disease or state that is not suitable for using these two drugs, or it will affect the interpretation of the research results or put the patient in a high-risk situation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete response rate (CR) | Up to 24 months | CR was defined as the percentage of participants who achieved CR, using the Lugano criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) | Up to 24 months | Percentage of participants with best overall response of partial response (PR) and complete response (CR), using the Lugano criteria. |
| Progressive free survival (PFS) | Up to 24 months | PFS was defined as the time from the date of treatment initiation to the date of first documentation of definitive disease progression (PD) or date of death from any cause, whichever occurs first. |
| Overall survival (OS) | Up to 24 months | OS will be measured from the date of registration to the date of the event (i.e., death) or the date of last follow-up to evaluate that event. Patients who are event-free at their last follow-up evaluation will be censored at that time point. |
Countries
China
Contacts
Primary ContactBing Xu
Backup ContactZhifeng Li
Outcome results
None listed